ranibizumab ophthalmic (Lucentis, Byooviz)

From Aaushi
Jump to navigation Jump to search

Introduction

Tradename: Lucentis (FDA approved 2006).

Aslo see more general term ranibizumab

Indications

Dosage

  • intavitreal injection of 0.3-0.5 mg monthly

Adverse effects

Mechanism of action

Notes

  • cost $2000/0.5 mg dose
  • according to the Washington Post, this is the same drug as bevacizumab (Avastin) both produced by Genentech[3]

More general terms

References

  1. Rosenfeld PJ et al Ranibizumab for neovascular age-related macular degeneration N Engl J Med 2006, 355:1419 PMID: https://www.ncbi.nlm.nih.gov/pubmed/17021318
    Brown DM et al Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 2006, 355:1432 PMID: https://www.ncbi.nlm.nih.gov/pubmed/17021319
    Steinbrook R. The price of sight - Ranibizumab, bevacizumab, and the treatment of macular degeneration. N Engl J Med 2006, 355:1409 PMID: https://www.ncbi.nlm.nih.gov/pubmed/17021315
    Stone EM. A very effective treatment for neovascular macular degeneration N Engl J Med 2006, 355:1493 PMID: https://www.ncbi.nlm.nih.gov/pubmed/17021326
  2. 2.0 2.1 2.2 2.3 FDA News Release: Aug. 10, 2012 FDA approves Lucentis to treat diabetic macular edema http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm315130.htm
  3. 3.0 3.1 Kliff S This $2,000 drug says everything about our messed up health- care system. Washington Post Dec 9, 2013 http://www.washingtonpost.com/blogs/wonkblog/wp/2013/12/09/this-2000-drug-says-everything-about-our-messed-up-health-care-system/
  4. 4.0 4.1 The Diabetic Retinopathy Clinical Research Network. Aflibercept, Bevacizumab, or Ranibizumab for Diabetic Macular Edema. N Engl J Med. 2015 Feb 18. <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/25692915 <Internet> http://www.nejm.org/doi/full/10.1056/NEJMoa1414264
    Martin DF, Maguire MG. Treatment Choice for Diabetic Macular Edema. N Engl J Med. 2015 Feb 18. [Epub ahead of print] <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/25692914 <Internet> http://www.nejm.org/doi/full/10.1056/NEJMe1500351